Charlotte Charpentier

Summary

Country: France

Publications

  1. Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, et al. Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. J Antimicrob Chemother. 2012;67:2231-5 pubmed publisher
    ..LLV seems to be a transient phenomenon that might be driven by residual ongoing viral replication and/or viral release and/or accuracy of viral load assay at lower values. ..
  2. Charpentier C, Lee G, Rodriguez C, Visseaux B, Storto A, Fagard C, et al. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response. J Antimicrob Chemother. 2015;70:2090-6 pubmed publisher
    ..However, these MRVs were not associated with an increased risk of virological failure, except for a trend for etravirine MRVs. ..
  3. Charpentier C, Koyalta D, Ndinaromtan M, Tchobkréo B, Jenabian M, Day N, et al. Distribution of HIV-1 and HSV-2 epidemics in Chad revealing HSV-2 hot-spot in regions of high-risk HIV spread. J Infect Dev Ctries. 2011;5:64-7 pubmed
    ..Urgent public health interventions are needed in regions of Chad where high HSV-2 prevalence may be increasing the risk of HIV propagation. ..
  4. Charpentier C, Piketty C, Laureillard D, Tisserand P, Si Mohamed A, Weiss L, et al. Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy. Eur J Clin Microbiol Infect Dis. 2012;31:129-33 pubmed publisher
    ..The potent action of RAL-containing treatment observed in the CD4 T cells compartment may suggest a pronounced reduced inhibition in the pool of regenerating CD4 T cells on a RAL-based therapy. ..
  5. Charpentier C, Camacho R, Ruelle J, Kaiser R, Eberle J, Gurtler L, et al. HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. Clin Infect Dis. 2013;56:1654-8 pubmed publisher
    ..hiv-grade.de). ..
  6. Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E, et al. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study. J Antimicrob Chemother. 2015;70:1881-4 pubmed publisher
  7. Charpentier C, Bellecave P, Cisse M, Mamadou S, Diakite M, Peytavin G, et al. High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger. Antivir Ther. 2011;16:429-33 pubmed publisher
    ..The prevalence of resistance was between 6% and 9% in both sites, which is higher than most of the other countries from Western Africa region. ..
  8. Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet J, et al. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Antivir Ther. 2011;16:937-40 pubmed publisher
  9. Charpentier C, Gody J, Tisserand P, Matta M, Pere H, Fournier J, et al. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic. Antivir Ther. 2011;16:1347-50 pubmed publisher
    ..These observations highlight the need to make an early diagnosis of the possibility of virological failure in Central African children receiving their first-line antiretroviral regimen. ..

More Information

Publications11

  1. Charpentier C, Talla F, Nguepi E, Si Mohamed A, Belec L. Virological failure and HIV type 1 drug resistance profiles among patients followed-up in private sector, Douala, Cameroon. AIDS Res Hum Retroviruses. 2011;27:221-30 pubmed publisher
    ..In conclusion, our observations highlight the absolute need for improving viral load assessment in resource-limited settings to prevent and/or monitor therapeutic failure. ..
  2. Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, et al. Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother. 2011;55:1293-5 pubmed publisher
    ..Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar. ..